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Summary  The  most  common  manifestation  of  HIV  in  the  kidney  is  HIV-associated
nephropathy  (HIVAN).  In  this  report,  we  describe  the  ﬁrst  documented  case  of  mem-
branous  glomerulonephritis  in  an  HIV-positive  individual  in  Turkey,  the  country  with
the  lowest  HIV  prevalence  in  the  region.  The  case  occurred  in  an  HIV-positive,  hepati-glomerulonephritis tis  C  (HCV)-negative,  and  hepatitis  B  (HBV)-negative  Caucasian  male,  who  presented
with  nephrotic-range  proteinuria.  The  patient  had  a  favorable  response  to  HAART
and  an  angiotensin-receptor  blocker.
©  2012  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
r
tntroductionIV-associated  nephropathy  (HIVAN)  is  character-
zed  clinically  by  proteinuria,  often  with  a  sudden
nset,  with  rapidly  progressive  renal  dysfunction
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he course  of  several  months  [1].  The  pathology
f HIVAN  is  characterized  by  the  triad  of  collaps-
ng focal  glomerular  sclerosis  (FGS),  microcystic
ubular dilation,  and  endothelial  cell  tubuloretic-
lar inclusions  [2].  HIVAN  was  initially  described
n 1984  by  Rao  et  al.,  who  reported  a  pattern
f sclerosing  glomerulopathy  in  HIV-1-seropositive
atients in  New  York  City  [3].  Although  approx-
mately half  of  the  patients  were  asymptomatic
nd had  not  suffered  from  opportunistic  infections
 Sciences. Published by Elsevier Ltd. All rights reserved.



















at  the  time  of  diagnosis,  all  had  CD4  cell  counts
of less  than  200  cells/mm3.  These  patients  may
present  with  nephrological  disorders.  HIVAN  is  espe-
cially prevalent  among  HIV-1-seropositive  patients
of African  descent  [4,5].  Herein,  we  present  the
ﬁrst well-documented  case  of  an  HIV-1-seropositive
Caucasian  male  patient  with  membranous  glomeru-
lonephritis  but  without  coinfections  associated
with membranous  nephropathy  in  Turkey,  the
country  with  the  lowest  HIV  prevalence  in  the
region.
Case report
A  55-year-old  man  was  admitted  to  our  hospi-
tal with  proteinuria  exceeding  3.5  g  per  day  as
determined  by  urine  analysis  during  a  routine  labo-
ratory evaluation.  He  had  no  further  complaints,
although HIV  seropositivity  had  been  detected  3
months previously.  The  physical  examination  was
normal. Laboratory  ﬁndings  were  as  follows:  Hgb:
11.0 g/dL,  Na:  126  mequiv/L,  albumin:  1.4  g/dL,
creatinine:  1.8  mg/dL,  CD4:  75/mm3,  and  HIV  RNA:
547,000 copies/ml.  He  tested  negative  for  toxo-
plasma,  syphilis  and  malaria.  The  urinary  sediment
revealed  severe  proteinuria.  The  glomerular  ﬁl-
tration rate  (GFR)  was  found  to  be  77  ml/min  as
predicted  by  the  24-h  creatinine  excretion  rate.
Proteinuria  of  6.7  g  per  day  was  detected  by  24-
h measurements  and  urine  analysis.  The  serum
complement  levels  were  normal.  Serum  protein
electrophoresis showed  a  broad-based  increase  in
the levels  of  gamma  globulins.  ANA  was  slightly
positive; cANCA  and  pANCA  were  negative.  The
patient  was  also  negative  for  HCV  and  HBV.  Further
investigation  excluded  malignancies  and  possi-
ble exposure  to  drugs.  Urinary  ultrasonography
revealed  increased  parenchymal  echogenicity  in
the right  kidney.
A renal  biopsy  was  performed,  and  a  total  of
18 glomeruli  were  observed  on  the  slides.  Three
of these  glomeruli  were  globally  sclerotic.  The
other  glomeruli  were  normocellular,  but  the  cap-
illary basement  membranes  were  signiﬁcantly  and
diffusely thickened.  The  mesangial  regions  were
slightly expanded  and  hypercellular  in  some  seg-
ments. The  interstitium  was  expanded  in  the
subcapsular  region  with  mononuclear  cell  inﬁltra-
tion (Fig.  1).  The  histopathological  abnormalities
observed in  the  renal  biopsy  specimen  were  consis-
tent with  membranous  glomerulonephritis.
A treatment  regimen  of  HAART  (consisting  of
lopinavir/ritonavir  + lamivudine  +  zidovudine)  and
valsartan  (40  mg/day)  was  commenced.  A  dietary
o
n
iigure  1  Diffuse  membranous  glomerulonephritis
H&E).
rotein  range  of  0.6—0.8  g/kg/day  was  suggested
s a  further  means  of  reducing  the  proteinuria.
fter 6  weeks  of  treatment,  his  serum  creatinine
evel was  1.28  mg/dL,  and  urine  analysis  revealed
.825  g/day  of  proteinuria.  The  patient  was  dis-
harged for  follow-up.  The  patient  is  currently  in
he second  year  of  treatment  with  15  mg/day  of
rotein in  the  urine,  a  serum  creatinine  level  of
.04 mg/dL,  a GFR  of  110  ml/min,  a  CD4  level  of
50/mm3 and  no  expression  of  HIV  RNA.
iscussion
urkey  has  one  of  the  lowest  prevalences  of
IV/AIDS in  central  Europe.  By  the  end  of  June
009, a total  of  3898  cases  had  been  identiﬁed  in
ur country,  which  has  a population  of  70  million
6].HIV-infected people  exhibit  a  wide  spectrum
f kidney  histopathologies.  Although  HIVAN  is
ow a well-characterized  renal  disease  present-































































[IV  infection  with  diffuse  membranous  glomerulone
ver-increasing  number  of  other  glomerulopathies
ncluding  amyloidosis,  minimal  change  disease,  dia-
etic nephropathy,  allergic  interstitial  nephritis,
nd  cryoglobulinemia  are  described  in  association
ith HIV  infection  [1,3,7].  Patients  with  HIVAN  usu-
lly present  with  symptoms  of  chronic  renal  failure
ccompanied  by  proteinuria  [1,3,4].
Membranous  nephropathy  has  been  reported
reviously in  HIV-infected  patients  [8,9].  However,
IV-associated  nephropathies  including  membra-
ous glomerulopathy  have  been  recently  reported
o occur  signiﬁcantly  more  frequently  in  individuals
oinfected  with  hepatitis  C  than  in  those  who  are
ot coinfected  [10].  Our  patient  did  not  have  any
oinfections  or  comorbidities  typically  associated
ith membranous  nephropathy.  He  presented  with
assive proteinuria  with  at  least  3  months  of  known
IV seropositivity.  He  was  asymptomatic  and  had  no
etectable opportunistic  infections.  Unfortunately,
he demonstration  of  viral  antigens  could  not  be
erformed  by  electron  microscopy  or  immunoﬂuo-
escence.
Renal echogenicity  may  be  increased  during  the
ltrasonographic  examination  [4].  Both  increased
chogenicity  of  the  right  kidney  and  diffuse  mem-
ranous  glomerulonephritis  were  observed  in  our
ase.
HAART prevents  the  progression  of  HIVAN
o end-stage  renal  failure.  Furthermore,  HAART
ecreases  the  development  of  HIVAN  by  60%
n risk  groups  [4,11,12]. Angiotensin-converting
nzyme  (ACE)  inhibitors  were  also  implicated  in
he prevention  of  HIVAN  in  some  studies  [1,4].
lthough  steroids  may  cause  signiﬁcant  decreases
n serum  creatinine  levels,  recurrences  were
bserved after  the  cessation  of  therapy  [4,13].
e began  to  treat  our  patient  with  both  HAART
nd an  angiotensin-receptor  blocker  and  observed
he regression  of  proteinuria  at  the  6th  week
f follow-up.  No  immunosuppressive  agent  was
sed.
In conclusion,  HIV  infection  can  lead  to  func-
ional and  structural  abnormalities  in  renal  tissue
t any  stage  of  the  disease.  HIV-associated  mem-
ranous  nephropathy  should  be  considered  in
aucasian  patients  with  HIV  infection  complicated
y nephrotic  syndrome  and  renal  failure  even
n the  absence  of  other  coinfections  and  comor-
idities typically  associated  with  membranous
ephropathy.  The  management  of  HIV-associated
idney diseases  requires  close  collaboration  among
nfectious  disease  specialists  and  nephrologists.
ew combination  therapies  including  protease
nhibitors, determination  of  HIV  disease  stage
y viral  load  detection  and  the  management  of
nfections  and  renal  diseases  at  early  stages  are
[itis  209
romising  modalities  in  the  reversal  of progression
o end-stage  renal  failure.
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